Could a Two-Drug HIV combo protect babies without extra side effects?
NCT ID NCT00424814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a simpler HIV drug combination (lopinavir/ritonavir alone) could safely prevent mothers from passing HIV to their babies during pregnancy, compared to the standard three-drug combo. About 105 pregnant women with well-controlled HIV took part. The goal was to see if the simpler regimen could keep virus levels low enough to protect the baby while reducing drug side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lopinavir/ritonavir (Kaletra) with or without zidovudine/lamivudine (Combivir)
What this could lead to
If successful, this could offer a safer, simpler way to prevent HIV transmission from mother to child during pregnancy, reducing drug side effects for both.
What could go wrong
This is a small, early-phase study (105 participants) that may not prove generalizable. The simpler regimen might not suppress the virus as well as standard combinations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Pitie salpetriere
Paris, 75013, France